STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers
Abstract
Prostate cancers show remarkable resistance to emerging immunotherapies, partly due to tolerogenic STAT3 signaling in tumor-associated myeloid cells. Here, we describe a novel strategy combining STAT3 inhibition with Toll-like Receptor 9 (TLR9) stimulation to unleash immune response against prostate cancers regardless of the genetic background.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2018
- Source ID
- 10.1158/1078-0432.ccr-18-1277
Entities
People
- Dayson Moreira
- Marcin Kortylewski
- Piotr Swiderski
- Ronald A. DePinho
- Seok Voon White
- Sumanta K. Pal
- Tomasz Adamus
- Xin Lu
- Xingli Zhao
- Yu-lin Su
- Zhuoran Zhang
Organizations
- City of Hope National Medical Center
- United States Department of Defense
- University of Notre Dame
- University of Texas at Austin